ASCO 2024: Priority Report: Updates in RCC

home / publications / supplements / asco-2024-priority-report-updates-in-rcc
Charlene Mantia, MD, of Dana-Farber Cancer Institute

Nivolumab/Cabozantinib Combination Prolongs Treatment-Free Survival in Advanced RCC

Kyle Doherty
June 6th 2024
Article

Partition overall survival data indicated that nivolumab plus cabozantinib extended treatment-free survival vs sunitinib in advanced renal cell carcinoma.

Brian Rini, MD

Higher T-Cell Inflamed GEP Values Are Positively Associated with Outcomes For Pembrolizumab/Axitinib in ccRCC

Megan Hollasch
June 5th 2024
Article

Higher T-cell inflamed GEP values were positively associated with clinical outcomes for pembrolizumab plus axitinib in advanced clear cell RCC.

Jens Hoeppner, FAChirg, FACS, MD

Lenvatinib Plus Pembrolizumab Delays Tumor Progression in All Organs vs Sunitinib in Advanced RCC

Kyle Doherty
June 5th 2024
Article

Lenvatinib/pembrolizumab offered a significant benefit in terms of time to disease progression in all organs vs sunitinib in advanced RCC.

Toni Choueiri, MD, of Dana-Farber Cancer Institute

Lenvatinib/Pembrolizumab Yields Greater Clinical Benefit vs Sunitinib Regardless of Biomarker Subtypes in ccRCC

Megan Hollasch
June 3rd 2024
Article

Lenvatinib plus pembrolizumab displayed a superior clinical benefit vs sunitinib irrespective of patient biomarker subtype in advanced clear cell RCC.

Sayed Matar, MBBChB, of Brigham and Women’s Hospital

mIF Biomarker Not Associated With Improved Outcomes With Nivolumab/Ipilimumab Treatment in Metastatic Clear Cell RCC

Megan Hollasch
June 2nd 2024
Article

Using CD8-positive, PD-1-positive, TIM3-negative, and LAG3-negative TILs as a biomarker was not associated with improved clinical outcomes for patients with mccRCC treated with nivolumab plus ipilimumab.